Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 13

1.

Importance of immunoglobulin heavy chain variable region mutational status in del(13q) chronic lymphocytic leukemia.

Gladstone DE, Swinnen L, Kasamon Y, Blackford A, Gocke CD, Griffin CA, Meade JB, Jones RJ.

Leuk Lymphoma. 2011 Oct;52(10):1873-81. doi: 10.3109/10428194.2011.585529. Epub 2011 Aug 18.

2.

Genetics of chronic lymphocytic leukemia: genomic aberrations and V(H) gene mutation status in pathogenesis and clinical course.

Stilgenbauer S, Bullinger L, Lichter P, Döhner H; German CLL Study Group (GCLLSG). Chronic lymphocytic leukemia.

Leukemia. 2002 Jun;16(6):993-1007. Review.

3.

IGHV mutational status testing in chronic lymphocytic leukemia.

Crombie J, Davids MS.

Am J Hematol. 2017 Dec;92(12):1393-1397. doi: 10.1002/ajh.24808. Epub 2017 Jul 29. Review.

PMID:
28589701
4.

Chronic lymphocytic leukemia: a clinical and molecular heterogenous disease.

Rodríguez-Vicente AE, Díaz MG, Hernández-Rivas JM.

Cancer Genet. 2013 Mar;206(3):49-62. doi: 10.1016/j.cancergen.2013.01.003. Epub 2013 Mar 24. Review.

PMID:
23531595
5.

First-line therapy for young patients with CLL.

Jain N, O'Brien S.

Hematology Am Soc Hematol Educ Program. 2016 Dec 2;2016(1):146-148. Review.

PMID:
27913473
6.

Genotypic prognostic markers.

Stilgenbauer S, Döhner H.

Curr Top Microbiol Immunol. 2005;294:147-64. Review.

PMID:
16323431
7.

Adverse prognostic features in chronic lymphocytic leukemia.

Mougalian SS, O'Brien S.

Oncology (Williston Park). 2011 Jul;25(8):692-6, 699. Review.

8.

The role of B cell receptor stimulation in CLL pathogenesis.

Kil LP, Yuvaraj S, Langerak AW, Hendriks RW.

Curr Pharm Des. 2012;18(23):3335-55. Review.

PMID:
22591389
9.

Update on therapy of chronic lymphocytic leukemia.

Gribben JG, O'Brien S.

J Clin Oncol. 2011 Feb 10;29(5):544-50. doi: 10.1200/JCO.2010.32.3865. Epub 2011 Jan 10. Review.

10.

Overview of recent developments in chronic lymphocytic leukemia.

Jain P, Rai KR.

South Asian J Cancer. 2012 Oct;1(2):84-9. doi: 10.4103/2278-330X.103721. Review.

11.

How should we sequence and combine novel therapies in CLL?

Davids MS.

Hematology Am Soc Hematol Educ Program. 2017 Dec 8;2017(1):346-353. doi: 10.1182/asheducation-2017.1.346. Review.

PMID:
29222277
12.

Chronic lymphocytic leukaemia: clinical translations of biological features.

Hamblin TJ.

Curr Top Microbiol Immunol. 2005;294:165-85. Review.

PMID:
16323432
13.

Identifying High-Risk Chronic Lymphocytic Leukemia: A Pathogenesis-Oriented Appraisal of Prognostic and Predictive Factors in Patients Treated with Chemotherapy with or without Immunotherapy.

Martinelli S, Cuneo A, Formigaro L, Cavallari M, Lista E, Quaglia FM, Ciccone M, Bardi A, Volta E, Tammiso E, Saccenti E, Sofritti O, Daghia G, Negrini M, Dabusti M, Tomasi P, Moretti S, Cavazzini F, Rigolin GM.

Mediterr J Hematol Infect Dis. 2016 Oct 15;8(1):e2016047. eCollection 2016. Review.

Supplemental Content

Support Center